Aptose Biosciences (NASDAQ:APTO) Upgraded by Alliance Global Partners to Strong-Buy Rating

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was upgraded by research analysts at Alliance Global Partners to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Several other equities research analysts have also issued reports on the company. StockNews.com started coverage on Aptose Biosciences in a research report on Tuesday. They set a “hold” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Aptose Biosciences in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Aptose Biosciences presently has a consensus rating of “Buy” and a consensus price target of $130.00.

Aptose Biosciences Stock Down 1.8 %

Shares of NASDAQ APTO opened at $3.19 on Thursday. Aptose Biosciences has a fifty-two week low of $3.05 and a fifty-two week high of $57.00. The business has a 50 day moving average price of $5.92 and a two-hundred day moving average price of $8.83. The firm has a market cap of $6.83 million, a PE ratio of -1.07 and a beta of 0.88.

Institutional Trading of Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Bleichroeder LP acquired a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned about 4.15% of Aptose Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.